Mako Surgical to raise $37M in public offering; Harvard University creates drug delivery sponge;

 @FierceMedDev: Medtronic gains expanded approval for ts Valiant Captivia stent graft system. More | Follow @FierceMedDev

 @MarkHFierce: Malaysia looking to beef up its medical device clinical testing capabilities. Item | Follow @MarkHFierce

 @DamianFierce: Mindray Medical is recalling anesthesia devices over a leak risk. News | Follow @DamianFierce

> Mako Surgical ($MAKO), a devicemaker focused on orthopedic implants and surgical tools, expects to raise at least $37 million in a public offering. Release

> The Cancer Treatment Centers of America will test NanoSectra Biosciences' nanoparticle therapy as a lung cancer treatment. It's designed to be absorbed by cells and then targeted with infrared lasers, offering an efficient way to destroy tumors. Story

> Sanovas hopes to raise $25 million so it can commercialize a next-generation medical device built to scan, diagnose and treat lung disease. Story

> CollaboRx, which aggregates genomics data to enable cancer diagnostics, faced rising net losses in its fiscal 2013 second quarter as it absorbed the cost of a merger. Tegal acquired CollabRx in July and kept the CollabRx name. Item

> Brandeis University scientists have developed an organic, lifeless gel that appears to move on its own, offering a potential new device to enable drug delivery. Story

> The cost of treating heart disease has become a major factor in treatment decisions, Reuters reports. Story

> Harvard University bioengineers came up with a gel-based sponge that can be loaded with drugs or stem cells. It can be molded to any shape, compressed to a fraction of its size and delivered by way of injection. Once in the body, the nimble device reaches its original size, releases its cargo and breaks down. Release

Biotech News

 @FierceBiotech: Protein biomarker predicts Type 2 diabetes years in advance. Story | Follow @FierceBiotech

 @JohnCFierce: Want to sell expensive cancer drugs in China? Get the middle class to buy health insurance. Via BMBG. Story | Follow @JohnCFierce

 @RyanMFierce: HepC pill race report 2012: $GILD, $ABT, $VRTX, others rush toward pharma gold. Report | Follow @RyanMFierce

> Pharma groups advance 221 new diabetes drugs as epidemic worsens. Article

> Bayer gambling $4B R&D budget on Xarelto, top blockbuster hopefuls. Story

Pharma News

@FiercePharma: $AZN's Seroquel franchise takes another hit: German court rules XR patent invalid. U.K. did already. Anyone else? More | Follow @FiercePharma

> Roche sells insurance to gin up paying customers in China. Story

> AMA lines up against pharma's pay-to-delay deals. News

> Genzyme resolves shortage of cancer drug Thyrogen. Article

> Pfizer, Protalix near Eleyso supply deal in Brazil. Report

Biomarkers News

> Biomarker tags AstraZeneca's clot buster activity in patient subgroup. Story

> Genetic mutations signpost inherited heart risk. Item

> Protein marker tags activity for GlaxoSmithKline drug in mesothelioma. More

> Fox Foundation funds BioFIND Parkinson's marker project. News

Drug Delivery News

> Injectable sponge stars and hearts deliver drugs. Story

> Optinose $2.1M grant to deliver autism treatment from the nose to the brain. Item

> Bacterial 'minicells' deliver cancer drugs straight to the target. More

> GSK, XenoPort terminate extended-release gabapentin deal. Article

Suggested Articles

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.